SCHEMBL30765747

SCHEMBL30765747

C[C@@H](Nc1cnc(-c2ccccc2F)n(CC(=O)O)c1=O)c1coc(-c2ccccc2)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 12/20 0.39
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
CASP1 P29466 1/20 0.33
CTSA P10619 1/20 0.33
MAPT P10636 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
ATR Q13535 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766054 0.90 ELANE (0.37) ELANEKDM4EALDH1A1
SCHEMBL30765924 0.88 GAA (0.45) ELANEMAPTGAAALDH1A1
SCHEMBL30765880 0.82 F3 (0.36) ELANE
SCHEMBL30765628 0.82 PDE2A (0.43) ELANECTSAKDM4E
SCHEMBL30765713 0.81 AKT1 (0.36) MAPTKDM4EALDH1A1
SCHEMBL30765827 0.81 AKT1 (0.36) MAPTKDM4EALDH1A1
SCHEMBL30765552 0.79 LMNA (0.38) KDM4EALDH1A1
SCHEMBL31558470 0.76 LMNA (0.37) ELANECTSAGAAKDM4EALDH1A1
SCHEMBL30766151 0.76 ELANE (0.37) ELANECTSAALDH1A1EGLN1
SCHEMBL30765981 0.76 LMNA (0.37) ELANECTSAGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed